Genotyping, SNP, Mutation and Biomarker Analysis
Eurofins Genomics offers comprehensive genetic analysis of sample groups. Both single samples as well as batches of several thousand samples can be processed. For example, we offer genotyping for clinical trials according to the Good Laboratory Practice, GLP (OECD Guideline No.1 on the Principles of Good Laboratory Practice (ENV/MC/CHEM(98)17) and in accordance with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, GCP (CPMP/ICH/135/95).
Using state-of-the-art techniques like Sanger sequ...
Using state-of-the-art techniques like Sanger sequencing, next generation sequencing, mass spectrometry (MALDI) and TaqMan, defined alleles and their underlying genetic polymorphisms of all genes can be analysed. These genes are typically of pharmacogenetic relevance and encode e.g. for drug-metabolizing enzymes. In addition to this, Eurofins Medigenomix also offers analysis of genes which play an important role in clinical diagnostics, e.g. genes for lactose intolerance/lactase persistence, for progressive lung disease (alpha-1-antitrypsin (AAT) - deficiency), of the human leucocyte antigen (HLA) complex and diverse cancer-related genes.
Based on provided sample material, as biofluids (e.g. blood samples), tissue samples or buccal swabs, analysis will be performed. Genomic DNA extracted from samples represents the starting material for genetic analyses. Naturally, DNA provided by the customer can be directly used as a starting material. During analysis the samples will be stored appropriately and safely at Eurofins Genomics. If the customer requests long-term storage of samples upon completion of analysis (biobanking), or if such sample storage is necessary due to regulatory requirements of GLP / GCP, then Eurofins Genomics offers professional sample storage via its sister company Eurofins Medinet. In case that only short-term or mid-term storage of samples are required, Eurofins Genomics offers professional sample storage at its facility.
Of course, we care about the documentation of all genotyping projects either according to your requirements or in compliance with official provisions e.g. GLP/GCP grade documentation including study plan and final report for analysis in the scope of clinical studies.
The assay portfolio of Eurofins Genomics includes analysis for the following pharmacogenetic relevant genes:
- Drug metabolizing enzymes, DMEs (Phase I enzymes/Cytochrome P450 enzymes, e.g. CYP2D6; Phase II enzymes, e.g. N-acetyl transferases)
- Drug transporters (Solute Carrier (SLC) - and ATP Binding Cassette (ABC) - transporters, e.g. organic cation transporters, OCTs, as members of the SLC family)
- Drug receptors (ligand controlled ion channels or class 1 receptors, e.g. glutamate receptor; G-protein coupled receptors (GPCRs) or class 2 receptors, e.g. ß-receptor; enzymatic receptors, e.g. insulin receptor; receptors regulating gene expression, e.g. steroid hormone receptor)
- G-proteins, e.g. GNAS1 or GNB3
- Human leucocyte antigens (HLA)
Customer reviews
No reviews were found for Genotyping, SNP, Mutation and Biomarker Analysis. Be the first to review!